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Microbiopsy Biomarker Profiling in a Superficial
MelanomaResembling a Pigmented Basal
Cell Carcinoma
The skinmicrobiopsydevice is aminimally invasive andpain-
less technique used as an alternative to conventional biopsy
techniques for collecting cells from the epidermis to the pap-
illary dermis for molecular diagnosis and research.1 We used
microbiopsy samples and quantitative polymerase chain re-
action (qPCR) analysis to differentiate between a histopatho-
logically proven superficial pigmented basal cell carcinoma
(BCC) (Figure 1A and B) and a superficial melanoma resem-
bling a pigmented BCC (index lesion from the case patient)
(Figure 1C and D).
Report of a Case |Aman in his 80s presentedwith an 8 × 4-mm
pigmented lesion, the index lesion, on his mid back. Dermos-
copy showed gray ovoid nests in the lower half of the lesion, a
spoke-wheel pattern at the 4- to 5-o’clock margin, and an
atypical, irregular broad pigment network at the 2-o’clock
margin (Figure 1C. Arborizing telangiectasia was absent, rais-
ing the possibility of pigmented BCC, melanoma, or, rarely, a
collision lesion. We compared the index lesion with a histo-
pathologically proven pigmented superficial and nodular BCC
that was obtained and processed in the same manner
(Figure 1B). Five microbiopsies were performed on represen-
tative parts across both lesions and in the perilesional skin in
both lesions. The exact sites of the microbiopsies are indi-
cated in Figure 1A and C. Using a Dermlite Cam, we obtained
dermoscopic photographs of the lesions before and after
microbiopsies were taken. A shave biopsy was subsequently
performed for histopathological diagnosis. Three of the 5
microbiopsy specimens were pooled for qPCR analysis, look-
ing for the expression of the melanoma signature genes
Tyr (NM_000372), CMIP (NM_198390.2), and LINC00518
(NR_027793.1)2 and a BCCmarker Gli1 (NM_005269.2).3
Results of qPCR showed that LINC00518 was upregu-
lated in the index sample by47-fold (Figure 2A). Therewasno
significantdifference in theexpressionofCMIPbetween these
Figure 1. Dermoscopic and Hematoxylin-Eosin–Stained Histopathologic Images of the Lesions
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Clinical (A) and histopathologic (B)
images of pigmented superficial basal
cell carcinoma (BCC): A, locations of
themicrobiopsies (arrowheads);
B, histopathologic analysis
demonstrates aggregations of
basaloid cells, palisading of nuclei,
and clefting. Clinical (C) and
histopathologic (D) images of
superficial melanoma: C, locations of
themicrobiopsies (arrowheads);
D, histopathologic analysis reveals
individual melanocytes and
irregularly distributed nests
predominantly along the basal layer
of the epidermis. Scale bars present
in panels C and D apply also to panels
A and B, respectively.
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samples (Figure2B).TheexpressionofTyr in the indexsample
was 10-fold higher than in the pigmented BCC sample
(Figure 2C). Gli1 was significantly overexpressed in the pig-
mented BCC sample by 24-fold (Figure 2D).
Histopathologic analysis showed a lentiginous mela-
nomaarising frommoderately to severely sun-damaged skin;
Breslow thickness, 0.2 mm; Clark level, 2 (Figure 1D).
Discussion | Pigmented BCC and melanoma can be difficult to
differentiate, both clinically and dermoscopically. Gene ex-
pression profiling has been performed to improve the diag-
nostic accuracy of melanoma4 and BCC.5
For this report, we used microbiopsy technology com-
bined with biomarker profiling to differentiate 2 lesions. Our
results showed that theexpressionofTyr in the index samples
was 10-fold higher than in the pigmented BCC control speci-
mens, suggesting that the index lesion contained a signature
for melanoma.6 Gli1, a critical transcriptional factor of the
Hedgehog/Patched signaling pathway,3(p132) is considered to
be a molecular marker for BCC.3(p135) Gli1 expression was de-
tected in our index sample but was 24-fold lower than in the
BCCcontrol specimens.Thehigh-levelTyrexpressionand low
expression of Gli1 suggested that the index sample was in-
deed a melanoma and not a BCC.
To confirm this hypothesis, we used a set of 2 markers,
LINC00518 and CMIP. This 2-gene molecular signature ap-
proachwasdesignedtodifferentiatemelanomafromneviusing
anadhesivepatch testmethodthat samples theepidermiswith
a sensitivity of 97.6% and a specificity of 72.7%.2(p240)
LINC00518 has been reported to be upregulated in mela-
noma,whereasCMIP is relativelydownregulated.Between the
index lesion from the present patient and the BCC lesion, we
observed a significant difference in the expression of
LINC00518, but we did not observe a difference in expres-
sion of CMIP levels, which may reflect differences in bio-
marker sampling sites from previously published reports.
Conclusions |Observations from our study suggest thatmicro-
biopsy is a promising sampling technique for skin cancer re-
search. It provides enough RNA for performing rapid, sensi-
tive, and specific qPCR andhas potential clinical applications
in research thatmay lead to future development for diagnos-
tic sampling in small, multiple lesions or in cosmetically sen-
sitive areas.
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Figure 2. The Expression of LINC00518 and CMIP, Tyr, andGli1 in Superficial Melanoma and Pigmented BCC
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A, LINC00518 expression level in themelanomawas 47-fold higher than in the
pigmented basal cell carcinoma (BCC) control lesion. B, CMIP expression
profiling revealed no significant differences in fold change between the
pigmented BCC and themelanoma. C, Tyr expression was 10-fold higher in the
indexmelanoma lesion than in pigmented BCC. D, The pigmented BCC control
lesion had 24-fold higher Gli1 expression than themelanoma. Error bars indicate
standard error.
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Secukinumab for Acrodermatitis Continua
of Hallopeau
Acrodermatitis continua of Hallopeau (ACH) was first de-
scribed in 1890byHenriHallopeau.1Hehadobserved a single
patient with an undulating but recalcitrant pustular destruc-
tionof the fingertipsandtoes.1Nowadays, thiscondition iscon-
sidered a subtype of localized pustular psoriasis.
There are no treatment guidelines available for ACH, and
the condition is refractory to many conventional topical and
systemic treatments.2 Several patients havebeen treatedwith
biologicagentswithvariable success.Targeted treatment strat-
egies based on pathogenic cytokine expression patterns have
not been evaluated for ACH.
Report of a Case |An 87-year-old retired electrical engineer had
recurrentepisodesof redness, swelling, andpurulentdischarge
intheareaof the lefthalluxwithprogressivedegenerationof the
toenailfor2years.Otherdigitswerenotinvolved.Antibiotictreat-
menthadbeenineffective.Theaffectedtoeshowedonychodys-
trophy, and the erythematous perionychium was beset with
pustules(Figure1A).Allothertoesandfingerswerenormal.Find-
ings of mycologic and bacterial swabs were negative. No signs
of systemic inflammationwere present.
Amedial longitudinal biopsyof thenail bedof the left hal-
lux revealed numerous neutrophils within the stratum cor-
neum, psoriasiform dermatitis with epidermal hyperplasia, a
lacking granular layer, and compact hyperkeratosis and para-
keratosis. These findings are compatiblewith thediagnosis of
acrodermatitis continua of Hallopeau (ACH). The patient, a
nonsmoker, didnothaveplaque-typepsoriasis but hada fam-
ily history of this condition. After ineffective treatment with
topical steroids,UV-Bphototherapy,andacitretin for9months,
the ACH flared to involve all fingers (Figure 1B). The Nail Pso-
riasis Severity Index score reached themaximum score of 80
points. On the pain visual analog scale, the patient reported
the maximum score, 10 of 10.
In generalized pustular psoriasis (GPP), interleukin
(IL)-17 mRNA levels are elevated.3 Even though they are dis-
tinct clinical entities, ACH and GPP are closely related on the
Figure 1. Clinical Findings
At presentationA Nine months after initial presentationB After treatmentC
A, Patient’s left big toe on initial presentation. B, Involvement of the fingers 9months later and shortly before initiation of treatment with secukinumab. C, Nine
weeks after treatment with secukinumab.
Figure 2. Histopathologic Findings
Normal skinA Affected skinB
200 µm 300 µm
A, Normal (uninvolved) non-acral skin
sample (interleukin [IL]-17 stain,
original magnification x400).
B, Acrodermatitis continua of
Hallopeau (involved) skin sample
from the left big toe (IL-17 stain,
original magnification x400).
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